While Infant Bacterial Therapeutics pushes towards pharmaceutical registration, MRM Health pioneers live microbial consortium therapies for IBD and Microbiotica accelerates into the clinic with assets for advanced melanoma and UC. The microbiome biotech pipeline is overflowing with compelling data, increasingly validating the transformative potential of microbiome-based therapies across diverse disease areas.

With the first LBP approvals on the horizon, but financial pressures threatening to slow progress, the 9th Microbiome Movement Summit Europe returns to Barcelona this January as the essential industry hub for R&D and business leaders determined to push the field forward.

Explore the latest advances in microbiome science, where innovative biotechs are uncovering new microbial targets, deciphering mechanisms of action and harnessing state-of-the-art analytical tools to uncover the microbiome’s role in disease. Engage with investors and C-level leaders as we strategise how to bring big pharma back into the fold of emerging microbial modalities.

Join a community of 100+ industry leaders to drive the future of microbial pipeline innovation in a sector bursting with therapeutic potential!

Visit microbiome-europe.com